SCHEMBL2641952

SCHEMBL2641952

CSc1ccc(O)c(C=O)c1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 13/20 0.52
MCL1 Q07820 1/20 0.52
ALDH1A1 P00352 1/20 0.47
CDK1 P06493 1/20 0.46
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16555488 0.87 ERN1 (0.47) ERN1MCL1CDK1TRIM24TRIM33
SCHEMBL8322156 0.84 TYR (0.52) ERN1MCL1ALDH1A1TRIM24TRIM33
SCHEMBL3899644 0.83 ERN1 (0.55) ERN1CDK1TRIM24TRIM33
SCHEMBL24254409 0.81 ERN1 (0.57) ERN1
SCHEMBL29399383 0.81 ERN1 (0.57) ERN1
SCHEMBL6094668 0.80 ERN1 (0.57) ERN1ALDH1A1CDK1TRIM24TRIM33
SCHEMBL3968110 0.78 ALDH1A1 (0.48) ERN1MCL1ALDH1A1
SCHEMBL3902703 0.77 NR1H2 (0.52) ERN1CDK1TRIM24TRIM33
SCHEMBL13946930 0.77 MAPT (0.54) MCL1ALDH1A1
SCHEMBL7493216 0.76 ALDH1A1 (0.47) ERN1MCL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059916-A Fluorescent probe for detecting divalent palladium and preparation method and application thereof 安徽中医药大学 2026-05-19 CN claimed
CN-122059916-A Fluorescent probe for detecting divalent palladium and preparation method and application thereof 安徽中医药大学 2026-05-19 CN disclosed
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 EP disclosed
CN-118715206-A Novel HDAC inhibitors and therapeutic uses thereof 探戈医药股份有限公司 2024-09-27 CN disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-RE49948-E1 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2024-04-30 US disclosed
EP-3586835-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING ARYL ETHERS PELOTON THERAPEUTICS INC (US) 2023-11-22 EP disclosed
US-5811459-A PAIN RELIEVERS ZENECA LIMITED (GB) 1998-09-22 US disclosed
EP-0835246-A1 AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZENECA LIMITED (GB) 1998-04-15 EP disclosed
WO-1997000863-A1 AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZENECA LIMITED (GB) 1997-01-09 WO disclosed
EP-0733033-A1 PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS ZENECA LIMITED (GB) 1996-09-25 EP disclosed
WO-1996011902-A1 PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS ZENECA LIMITED (GB) 1996-04-25 WO disclosed
EP-0167371-B1 DIHYDROPYRIDINE COMPOUNDS, THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-03-06 EP disclosed
US-4727082-A CARDIOVASCULAR DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1988-02-23 US disclosed
EP-0167371-A2 Dihydropyridine compounds, their production, and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1986-01-08 EP disclosed
US-3944674-A Combating insects with o dimethoxymethylphenyl-N-methylcarbamate CIBA-GEIGY AG (CH) 1976-03-16 US disclosed
US-3933858-A INSECTICIDES CIBA-GEIGY AG (CH) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 ERN1 1971/4885MCL1 180/4885ALDH1A1 477/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 ERN1 1971/4885MCL1 180/4885ALDH1A1 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.